News & Updates
Filter by Specialty:
MUC5B minor allele tied to older age, better survival in IPF
In patients with idiopathic pulmonary fibrosis (IPF) aged >56 years, carrying the MUC5B minor allele translates to improved median transplant-free survival at 16 months, results of a retrospective study in Europe have shown.
MUC5B minor allele tied to older age, better survival in IPF
30 Apr 2023
Older IBD patients at disadvantage for medications, surgery
Older patients with inflammatory bowel disease (IBD) are less likely to be initiated on medications and are often scheduled for surgeries, a study has found.
Older IBD patients at disadvantage for medications, surgery
29 Apr 2023
Clindamycin delivers in bacterial vaginosis
Use of a single dose of a new bioadhesive 2% clindamycin vaginal gel in the treatment of bacterial vaginosis appears to result in a rapid resolution of symptoms, with high acceptability among women, as reported in a study.
Clindamycin delivers in bacterial vaginosis
29 Apr 2023
Comorbidities fewer prior to onset of giant cell arteritis
Patients with giant cell arteritis (GCA) have a lower prevalence of diabetes mellitus as well as median fasting blood glucose (FBG) and body mass index (BMI) up to 5 years prior to diagnosis, according to a study, indicating the influence of metabolic factors on the risk of GCA.
Comorbidities fewer prior to onset of giant cell arteritis
29 Apr 2023
New ARIA technology improves CVD risk estimates in high-risk individuals with HIV
Researchers from the Chinese University of Hong Kong (CUHK) have developed an automatic retinal image analysis (ARIA) technology that utilizes machine learning to improve cardiovascular disease (CVD) risk estimates in people living with HIV (PLWH) who have cardiovascular (CV) risk factors.
New ARIA technology improves CVD risk estimates in high-risk individuals with HIV
29 Apr 2023
Tralokinumab a promising treatment option in young people with moderate-to-severe AD
Targeting interleukin (IL)-13 with tralokinumab monotherapy helps reduce disease activity in adolescents with moderate-to-severe atopic dermatitis (AD) with a low frequency of conjunctivitis throughout the treatment period, according to data from the phase III ECZTRA 6 trial.
